OTC:CC - Ocumetics Announces Design Lockdown to Enter Further Development Stages
(TheNewswire)
Calgary, Alberta – TheNewswire - April 19, 2023 - Ocumetics Technology Corp. (“ Ocumetics ” or the“ Company ”) ( TSXV:OTC) (OTC:OTCFF) (FRA:2QBO)is pleased to announce that its research and development team hassuccessfully completed design lockdown for the Ocumetics accommodatinglens that will move into the next stage of testing.
“This announcement represents the completion ofthousands of hours of design work and bench studies optimizingimplantation characteristics and lens functionality,” said Dr. MarkLee, President & CEO of Ocumetics. “Kudos to Dr. Garth Webb, theFounder and Chief Scientific Officer of Ocumetics, and the engineersat Bioana, in Monterrey, Mexico, for their creativity, innovation andpersistence in getting us to this stage.”
“This is a significant milestone for Ocumetics, as itplants a flag in the ground from which we can move forward”, saidDr. Webb. “This design lockdown allows Ocumetics to proceed with thebiocompatibility studies, shelf life studies, and other requiredtesting leading up to the first-in-human study, also known as a Proofof Concept study, which will begin once preclinical studies arecompleted.”
The last of the biocompatibility preclinical studiesfor the Ocumetics accommodating lens will be a 3-month in vivo animal study which is scheduled to commence in Q3 2023.
About Ocumetics
Ocumetics Technology Corp. (TSXV: OTC) (OTCQB: OTCFF)(FRA: 2QBO) is a Canadian research and development company thatspecializes in adaptive intraocular lens designs. Ocumetics is inthe preclinical study stage of a game-changing technology for theophthalmic industry. Ocumetics has developed an expandableintraocular lens that fits within the capsular bag followingextracapsular cataract extraction. It is designed to allow theeye’s natural muscle activity to shift focus from distance to near,potentially to eliminate the need for corrective lenses.
FOR FURTHER INFORMATION, PLEASECONTACT:
Dr. Mark Lee
President and CEO
(604) 832-6052
Neither the TSXVenture Exchange nor its Regulation Services Provider (as that term isdefined in the policies of the TSX Venture Exchange) acceptsresponsibility for the adequacy or accuracy of this release.
CAUTIONARY STATEMENT REGARDING FORWARD-LOOKINGINFORMATION: This news release includes certain “forward-lookingstatements” under applicable Canadian securities legislation. Forward-looking statements include, but are not limited to,statements with respect to the commencement, timing and scope of theclinical trial program outlined above and that it will be conducted asexpected. Forward-looking statements are necessarily based upon anumber of estimates and assumptions that, while considered reasonable,are subject to known and unknown risks, uncertainties, and otherfactors which may cause the actual results and future events to differmaterially from those expressed or implied by such forward-lookingstatements. Such factors include but are not limited to: operationalmatters, historical trends, current conditions and expected futuredevelopments, access to financing as well as other considerations thatare believed to be appropriate in the circumstances. There can be noassurance that such statements will prove to be accurate, as actualresults and future events could differ materially from thoseanticipated in such statements. Accordingly, readers should not placeundue reliance on forward-looking statements. The Corporationdisclaims any intention or obligation to updateor revise any forward-looking statements, whether as a result of newinformation, future events or otherwise, except as required bylaw.
Copyright (c) 2023 TheNewswire - All rights reserved.